FINWIRES · TerminalLIVE
FINWIRES

$INSM

8 stories mentioning INSMUpdated 18d ago

Every FINWIRES story that references INSM, newest first.

International

US Equity Markets End Lower Amid Technology Stock Sell-Off, Stronger-Than-Expected Jobs Data

US equity indexes were lower on Friday amid a sell-off in mega-cap tech stocks following a stronger-than-expected jobs report.* Nonfarm payrolls surged by 172,000 in May, above the 88,000 jobs increase expected in a Bloomberg-compiled survey. April was revised upwards to a 179,000 increase, and March payrolls were revised upwards to a 214,000 increase, the Bureau of Labor Statistics said Friday.* The probability of a 25 basis-point increase in interest rates in December surged to 43%, from 36% a week ago, according to the CME FedWatch tool.* July West Texas Intermediate crude oil fell $2.76 to settle at $90.28 per barrel, while August Brent crude, the global benchmark, was last seen down $2.12 at $92.91.* Cooper (COO) shares were up about 8.6%, the top gainer on S&P 500, after the company reported stronger-than-expected growth in fiscal Q2 adjusted earnings and sales.* Insmed (INSM) shares were down roughly 10%, among the steepest decliners on the Nasdaq, after RBC Capital Markets said Friday that brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug.

Dow JonesNasdaq CompositeS&P 500$COO$INSM
Wire

Sector Update: Healthcare

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) declined 1.8%.In corporate news, Insmed (INSM) brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug, RBC Capital Markets said Friday. Insmed shares were down 11%.

$INSM
Wire

Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says

Insmed (INSM) brensocatib shows strong physician conviction alongside a broad prescribing intent that can enable a significant growth opportunity as doctors develop experience with the drug, RBC Capital Markets said in a Friday note.The brokerage said its key opinion leader has depicted a strong growth opportunity for brensocatib, marketed as Brinsupri, in his practice based on its compelling efficacy with no new exacerbations observed to date in his experience, strong safety with no discontinuations in more than 60 patients and only a single dose reduction, and a generally permissive payer environment, albeit with some pockets of stringency such as the VA system.The KOL mentioned that patient enthusiasm for Brinsupri is notably high with many patients already having heard about the drug through support groups, RBC said, adding that compliance is strong, attributed to it being a once-daily oral pill relative to more burdensome existing regimens.The investment firm added that it continues to see upside to the company's $1 billion sales estimate for the drug in 2026.RBC lowered its price target to $195 from $205 and maintained its outperform rating.Shares of Insmed were down more than 7.7% in Friday trading.Price: $96.90, Change: $-8.03, Percent Change: -7.65%

$INSM
Insider Trading

Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing

Michael Alexander Smith, Chief Legal Officer, on May 22, 2026, sold 6,149 shares in Insmed (INSM) for $666,982. Following the Form 4 filing with the SEC, Smith has control over a total of 41,613 common shares of the company, with 41,613 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000187027826000015/xslF345X05/wk-form4_1779481519.xml

$INSM
Wire

Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says

Insmed (INSM) stock sell-off post Q1 results is overdone as underlying metrics appear positive and potential organic patient additions throughout the year should enable Brinsupri for non-cystic fibrosis bronchiectasis to clear the $1 billion floor with cushion, RBC Capital Markets said in a research note emailed Friday.The stock reaction could be due to investor concerns about a slump in patient additions and compliance, but the brokerage said it maintained its full-year 2026 Brinsupri sales guidance of around $1.3 billion.RBC concurs with Insmed's view that opportunity to ramp patient count through "doc experience" with Brinsupri could be considerable, while the pulmonary community presents an opportunity for future tailwinds as the company focuses on marketing and diagnostics, according to the note.There will be a balance between compliance creeping down, tightening of approval rates, future competitors, and the pool of latent patients that can be activated, which could drive $8 billion in US peak sales, analysts wrote.The brokerage said it reiterated its outperform rating on the stock and cut its price target to $205 per share from $220.Price: $99.51, Change: $-5.29, Percent Change: -5.05%

$INSM
Wire

RBC Cuts Price Target on Insmed to $205 From $220, Keeps Outperform Rating

Insmed (INSM) has an average rating of buy and mean price target of $212.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $100.81, Change: $-4.00, Percent Change: -3.81%

$INSM
Insider Trading

Insmed Insider Sold Shares Worth $1,469,442, According to a Recent SEC Filing

William Lewis, Director, Chair and CEO, on May 04, 2026, sold 10,699 shares in Insmed (INSM) for $1,469,442. Following the Form 4 filing with the SEC, Lewis has control over a total of 535,109 common shares of the company, with 301,185 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000026/xslF345X05/wk-form4_1778098286.xml

$INSM
Wire

Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says

Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.Price: $152.47, Change: $+1.33, Percent Change: +0.88%

$INSM

Track with the FINWIRES app suite

FolioX
FolioX
Track INSM in your portfolio
WheelAI
WheelAI
Analyze INSM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on INSM